Why Did UTHR Stock Surge Over 19% Pre-Market Today?

The company reported that its TETON-1 study to treat lung disease met its primary endpoint.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Shivani Kumaresan·Stocktwits

Published Mar 30, 2026 | 7:26 AM EDT

Add us on

United Therapeutics Corp. (UTHR) announced on Monday that its TETON-1 trial of nebulized Tyvaso in the treatment of idiopathic pulmonary fibrosis (IPF) achieved its primary goal.

The therapy demonstrated improvement in absolute forced vital capacity (FVC), outperforming placebo by 130.1 mL from baseline to week 52, giving new hope for patients with the debilitating lung disease.

The treatment not only met its main efficacy endpoint but also reduced the risk of clinical worsening.

Following the update, United Therapeutics’ stock traded over 19% higher in Monday’s premarket.

Get updates to this developing story directly on Stocktwits.